JP2021510710A5 - - Google Patents
Info
- Publication number
- JP2021510710A5 JP2021510710A5 JP2020539000A JP2020539000A JP2021510710A5 JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5 JP 2020539000 A JP2020539000 A JP 2020539000A JP 2020539000 A JP2020539000 A JP 2020539000A JP 2021510710 A5 JP2021510710 A5 JP 2021510710A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- nos
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018072607 | 2018-01-15 | ||
| CNPCT/CN2018/072607 | 2018-01-15 | ||
| PCT/CN2019/071711 WO2019137548A1 (en) | 2018-01-15 | 2019-01-15 | Antibodies and variants thereof against tigit |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021510710A JP2021510710A (ja) | 2021-04-30 |
| JP2021510710A5 true JP2021510710A5 (cg-RX-API-DMAC7.html) | 2022-02-07 |
| JP7316284B2 JP7316284B2 (ja) | 2023-07-27 |
Family
ID=67219401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539000A Active JP7316284B2 (ja) | 2018-01-15 | 2019-01-15 | Tigitに対する抗体及びその多様体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11708410B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3740508A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7316284B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200109313A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111601826B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019207296A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3088332A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL275737A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202005595YA (cg-RX-API-DMAC7.html) |
| TW (1) | TW201932489A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019137548A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
| EP4147053B1 (en) | 2020-05-07 | 2026-01-28 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
| US20240002500A1 (en) * | 2020-11-23 | 2024-01-04 | Guangdong Fapon Biopharma Inc. | Anti-TIGIT Antibody or Antigen-Binding Fragment Thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN114539418A (zh) * | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| CA3217279A1 (en) | 2021-05-04 | 2022-11-10 | Olga Ignatovich | Anti-tigit antibodies and methods of use thereof |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN115466327B (zh) * | 2021-06-10 | 2025-07-08 | 北京天广实生物技术股份有限公司 | 结合tigit的抗体及其用途 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| KR20240046905A (ko) * | 2021-08-20 | 2024-04-11 | 아케소 바이오파마, 인크. | 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023138639A1 (zh) * | 2022-01-24 | 2023-07-27 | 原启生物科技(上海)有限责任公司 | 靶向tigit的抗原结合蛋白及其用途 |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック, インコーポレイテッド | 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| WO2024041639A1 (en) * | 2022-08-26 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Antibodies targeting tigit and uses thereof |
| CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| CN121219319A (zh) * | 2023-06-27 | 2025-12-26 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| CN117343182B (zh) * | 2023-10-11 | 2024-12-03 | 首都医科大学附属北京胸科医院 | 抗人tigit抗体或其功能性片段及其应用 |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| CN118290586B (zh) * | 2024-04-02 | 2025-11-04 | 郑州伊美诺生物技术有限公司 | 一种分泌kod dna聚合酶单克隆抗体的杂交瘤细胞、单克隆抗体及其应用 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073644B (zh) * | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
| MX2016017288A (es) * | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| CA2957722C (en) | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| US10717783B2 (en) * | 2014-12-22 | 2020-07-21 | Zeren Gao | Bispecific tetravalent antibodies and methods of making and using thereof |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
| EP3337517A4 (en) * | 2015-08-20 | 2019-04-17 | Abbvie Stemcentrx LLC | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE |
| SG10202007764TA (en) * | 2015-09-25 | 2020-09-29 | Genentech Inc | Anti-tigit antibodies and methods of use |
| PT3356413T (pt) * | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| EP3565839A4 (en) * | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
-
2019
- 2019-01-15 JP JP2020539000A patent/JP7316284B2/ja active Active
- 2019-01-15 CA CA3088332A patent/CA3088332A1/en active Pending
- 2019-01-15 EP EP19738954.7A patent/EP3740508A4/en not_active Withdrawn
- 2019-01-15 KR KR1020207020419A patent/KR20200109313A/ko not_active Withdrawn
- 2019-01-15 WO PCT/CN2019/071711 patent/WO2019137548A1/en not_active Ceased
- 2019-01-15 TW TW108101551A patent/TW201932489A/zh unknown
- 2019-01-15 CN CN201980008439.XA patent/CN111601826B/zh active Active
- 2019-01-15 US US15/733,364 patent/US11708410B2/en active Active
- 2019-01-15 SG SG11202005595YA patent/SG11202005595YA/en unknown
- 2019-01-15 AU AU2019207296A patent/AU2019207296A1/en not_active Abandoned
-
2020
- 2020-06-29 IL IL275737A patent/IL275737A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7813721B2 (ja) | Nectin-4に対する抗体及びその用途 | |
| JP7150880B2 (ja) | 抗-b7-h3抗体およびその用途 | |
| JP7562528B2 (ja) | 抗体及びその用途 | |
| CN115052895B (zh) | 抗SIRPα抗体及其用途 | |
| US20170210818A1 (en) | Constant region antibody fusion proteins and compositions thereof | |
| JP2021524242A (ja) | 抗−ror1抗体およびその用途 | |
| JP7649744B2 (ja) | Btn3a結合タンパク質及びその使用 | |
| WO2018053709A1 (en) | The novel monoclonal antibodies to programmed death 1 (pd-1) | |
| JP2015519375A5 (cg-RX-API-DMAC7.html) | ||
| JP2019527553A5 (cg-RX-API-DMAC7.html) | ||
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2020508655A5 (cg-RX-API-DMAC7.html) | ||
| CN111635458A (zh) | 靶向Sirpα的抗体或其抗原结合片段及其制备和应用 | |
| JP2024001073A5 (cg-RX-API-DMAC7.html) | ||
| JP7821159B2 (ja) | Bcmaと結合する単一可変ドメイン及び抗原結合分子 | |
| WO2022045247A1 (ja) | 抗切断型変異calr-cd3二重特異性抗体及び医薬組成物 | |
| CN113993901A (zh) | 四价双特异性抗体、其制备方法和用途 | |
| JP2024515560A5 (cg-RX-API-DMAC7.html) | ||
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| CA3208368A1 (en) | Vegfa-binding molecules | |
| WO2021084104A1 (en) | Tetravalent antibody molecules | |
| JP7821161B2 (ja) | Bcmaと結合する単一可変ドメイン及び抗原結合分子 | |
| US20250011431A1 (en) | Anti-canine pd-l1 antibodies | |
| WO2020039049A1 (en) | Anti-sirpg compounds | |
| CN120035609A (zh) | Pd-1激动剂抗体 |